Program
Lenalidomide
Also written as “lenalidomide”, “CC-5013” and “Drug: Carfilzomib + Lenalidomide + Dexamethasone”.
Its studies are mostly in Multiple Myeloma · Lymphoma, Large B-Cell, Diffuse · Myelodysplastic Syndromes · Lymphoma, Non-Hodgkin · Lymphoma, Mantle-Cell, led by 6 companies.
Drug pageLenalidomide: every studyMany companies study it; this page follows only the 78 they lead. All 751 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibbits history only | 670 open or running | phase 3since Mar 5, 2003 | Aug 16, 2002 | none ahead |
| Takedaits history only | 50 open or running | phase 4since May 30, 2017 | Jul 25, 2007 | none ahead |
| Oncotherapeuticsits history only | 32 open or running | phase 2since Jul 30, 2014 | Jul 30, 2014 | none ahead |
| bionor-immuno-asits history only | 10 open or running | phase 2since Sep 11, 2012 | Sep 11, 2012 | none ahead |
| Samyang Biopharmaceuticalsits history only | 10 open or running | phase 1since Jun 25, 2017 | Jun 25, 2017 | none ahead |
| starton-therapeutics-incits history only | 11 open or running | phase 2since Sep 20, 2023 | Sep 20, 2023 | May 31, 2027phase 2 · NCT06087653 |
Also a collaborator on its studies: AbbVie, Prologue Research International, Karyopharm Therapeutics, Incyte, Johnson & Johnson, Abbott, ICON Clinical Research and Hoffmann-La Roche.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Sep 10, 2005.
- Nov 4, 2014Phase 3 study in Lymphoma, Large B-Cell, DiffuseBristol-Myers Squibb · NCT02285062 · 570 enrolled · United States, Australia, Belgium and more
- Jan 23, 2015Phase 2 study in Multiple MyelomaBristol-Myers Squibb · NCT02348528 · 65 enrolled · China
- Aug 11, 2015Phase 1 study in Healthy VolunteersBristol-Myers Squibb · NCT02521714 · 28 enrolled · United States
- Aug 25, 2015Phase 2 study in Leukemia, MyeloidBristol-Myers Squibb · NCT02538965 · 17 enrolled · United States, Canada
- Feb 16, 2016Phase 2 study in Multiple MyelomaBristol-Myers Squibb · NCT02685826 · 56 enrolled · United States, Canada, Denmark and more
- Sep 22, 2016Phase 2 study in Relapsed and/or Refractory Multiple MyelomaTakeda · NCT02917941 · 34 enrolled · Japan
- Feb 27, 2017Phase 1 study in Multiple MyelomaOncotherapeutics · NCT03110822 · 134 planned · United States
- May 30, 2017Phase 4 study in Multiple MyelomaTakeda · NCT03173092 · 141 enrolled · United States
- Jun 25, 2017Samyang Biopharmaceuticals’ first study: phase 1 study in Healthy, MaleNew to Samyang BiopharmaceuticalsSamyang Biopharmaceuticals · NCT03208218 · 42 enrolled
- Jan 23, 2018Phase 4 study in Relapsed and/or Refractory Multiple MyelomaTakeda · NCT03416374 · 45 enrolled · Japan
- Aug 16, 2018Phase 3 study in Multiple MyelomaBristol-Myers Squibb · NCT03651128 · 386 enrolled · United States, Belgium, Canada and more
- Aug 12, 2020Phase 1 study in Multiple MyelomaOncotherapeutics · NCT04519476 · 22 planned · United States
- Dec 20, 2021Phase 4 study in Multiple MyelomaTakeda · NCT05183139
- Sep 20, 2023starton-therapeutics-inc’s first study: phase 2 study in Multiple MyelomaNew to starton-therapeutics-incstarton-therapeutics-inc · NCT06087653 · 24 planned · United States
Ahead
- May 31, 2027Primary completion: phase 2 study in Multiple Myelomastarton-therapeutics-inc · NCT06087653
TargetBeta
“CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator”ChEMBL 37, by rule
Other programs on the same 4 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| pomalidomiderule | Bristol-Myers Squibb | phase 4 | 51 |
Studies
The newest 60 of 78 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06087653Multiple Myeloma · United States | 2 | Recruiting | starton-therapeutics-inc | May 31, 2027 | 24 |
| NCT05183139Multiple Myeloma | 4 | Withdrawn | Takeda | Dec 31, 2026 | 0 |
| NCT04519476Multiple Myeloma · United States | 1 | Recruiting | Oncotherapeutics | Dec 29, 2023 | 22 |
| NCT03651128Multiple Myeloma · United States, Belgium, Canada and more | 3 | Completed | Bristol-Myers Squibb | Apr 13, 2026 | 386 |
| NCT03416374Relapsed and/or Refractory Multiple Myeloma · Japan | 4 | Completed | Takeda | May 28, 2021 | 45 |
| NCT03208218Healthy, Male | 1 | Completed | Samyang Biopharmaceuticals | Aug 25, 2016 | 42 |
| NCT03173092Multiple Myeloma · United States | 4 | Terminated | Takeda | Mar 30, 2026 | 141 |
| NCT03110822Multiple Myeloma · United States | 1 | Recruiting | Oncotherapeutics | Sep 2024 | 134 |
| NCT02917941Relapsed and/or Refractory Multiple Myeloma · Japan | 2 | Completed | Takeda | Aug 31, 2019 | 34 |
| NCT02685826Multiple Myeloma · United States, Canada, Denmark and more | 2 | Completed | Bristol-Myers Squibb | Dec 15, 2017 | 56 |
| NCT02538965Leukemia, Myeloid · United States, Canada | 2 | Completed | Bristol-Myers Squibb | Jul 22, 2017 | 17 |
| NCT02521714Healthy Volunteers · United States | 1 | Completed | Bristol-Myers Squibb | Sep 23, 2015 | 28 |
| NCT02348528Multiple Myeloma · China | 2 | Completed | Bristol-Myers Squibb | Sep 29, 2016 | 65 |
| NCT02285062Lymphoma, Large B-Cell, Diffuse · United States, Australia, Belgium and more | 3 | Completed | Bristol-Myers Squibb | Mar 15, 2019 | 570 |
| NCT02206425Multiple Myeloma · United States | 2 | Completed | Oncotherapeutics | Jan 19, 2018 | 45 |
| NCT02155634Multiple Myeloma | 3 | Withdrawn | Bristol-Myers Squibb | Apr 2017 | 0 |
| NCT02112175Multiple Myeloma · Belgium, France, Greece and more | 3 | Completed | Bristol-Myers Squibb | Oct 12, 2020 | 46 |
| NCT01996865Lymphoma, Non-Hodgkin · United States, Germany, Puerto Rico | 3 | Completed | Bristol-Myers Squibb | May 11, 2024 | 503 |
| NCT01938001Lymphoma, Non-Hodgkin · United States, Belgium, Brazil and more | 3 | Completed | Bristol-Myers Squibb | Jun 22, 2018 | 358 |
| NCT01891643Newly Diagnosed, Previously Untreated Multiple Myeloma · United States, Greece, Italy and more | 3 | Terminated | Bristol-Myers Squibb | Jun 25, 2020 | 23 |
| NCT01724177Leukemia-Lymphoma, Adult T-Cell · Japan | 2 | Completed | Bristol-Myers Squibb | Nov 20, 2014 | 26 |
| NCT01698801Multiple Myeloma · Japan | 2 | Completed | Bristol-Myers Squibb | Nov 26, 2013 | 26 |
| NCT01704781Infections · Germany | 2 | Completed | bionor-immuno-as | Aug 2014 | 36 |
| NCT01593410Multiple Myeloma · China | 2 | Completed | Bristol-Myers Squibb | Jan 3, 2013 | 194 |
| NCT01476787Lymphoma, Follicular · United States, Japan | 3 | Completed | Bristol-Myers Squibb | Apr 30, 2024 | 1,030 |
| NCT01358734Leukemia, Myeloid, Acute · United States, Canada | 2 | Completed | Bristol-Myers Squibb | May 19, 2015 | 88 |
| NCT01197560Lymphoma, Large B-Cell, Diffuse · United States, Australia, Austria and more | 3 | Completed | Bristol-Myers Squibb | Jul 4, 2013 | 111 |
| NCT01169298Leukemia-Lymphoma, Adult T-Cell · Japan | 1 | Completed | Bristol-Myers Squibb | Dec 1, 2013 | 13 |
| NCT01032291Colorectal Neoplasms · Australia, Belgium, Germany and more | 2 | Terminated | Bristol-Myers Squibb | Jan 2011 | 51 |
| NCT01029262Anemia · United States, Australia, Austria and more | 3 | Completed | Bristol-Myers Squibb | Mar 17, 2013 | 239 |
| NCT01021423Lymphoma, Mantle-Cell · United States, Czechia, France and more | 3 | Terminated | Bristol-Myers Squibb | Mar 1, 2011 | 9 |
| NCT00988208Prostatic Neoplasms · United States, Australia, Austria and more | 3 | Completed | Bristol-Myers Squibb | Jan 13, 2012 | 1,059 |
| NCT00975806Carcinoma, Renal Cell · United States | 2 | Terminated | Bristol-Myers Squibb | Oct 1, 2011 | 16 |
| NCT00963105Recurrence · United States, Canada, France and more | 2 | Completed | Bristol-Myers Squibb | Sep 5, 2017 | 104 |
| NCT00928486Multiple Myeloma · Japan | 3 | Completed | Bristol-Myers Squibb | Sep 10, 2010 | 25 |
| NCT00910910Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more | 3 | Completed | Bristol-Myers Squibb | Mar 31, 2014 | 450 |
| NCT00910858Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS) · United States | 2 | Completed | Bristol-Myers Squibb | Apr 2006 | 40 |
| NCT00875667Lymphoma, Mantle-Cell · Belgium, Czechia, Denmark and more | 2 | Completed | Bristol-Myers Squibb | Jun 28, 2018 | 254 |
| NCT00812968Myelodysplastic Syndromes · Japan | 2 | Completed | Bristol-Myers Squibb | Sep 1, 2010 | 11 |
| NCT00774345Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more | 3 | Completed | Bristol-Myers Squibb | Oct 27, 2020 | 317 |
| NCT00737529Lymphoma, Mantle-Cell · United States, Austria, Belgium and more | 2 | Completed | Bristol-Myers Squibb | Apr 6, 2016 | 134 |
| NCT00689936Multiple Myeloma · United States, Australia, Austria and more | 3 | Completed | Bristol-Myers Squibb | Jul 14, 2016 | 1,623 |
| NCT00655668Lymphoma, T-Cell · United States, Australia, Belgium and more | 2 | Terminated | Bristol-Myers Squibb | Mar 1, 2010 | 54 |
| NCT00622336Multiple Myeloma · Russian Federation, Ukraine | 3 | Completed | Bristol-Myers Squibb | Nov 25, 2013 | 330 |
| NCT00555100Multiple Myeloma · Japan | 1 | Completed | Bristol-Myers Squibb | Dec 1, 2010 | 15 |
| NCT00507442Multiple Myeloma · United States | 2 | Completed | Takeda | Oct 2010 | 158 |
| NCT00478777Recurrence · Germany | 3 | Completed | Bristol-Myers Squibb | Nov 2007 | 150 |
| NCT00474188Lymphoma, Large B-Cell, Diffuse · United States, Australia, Canada | 2 | Terminated | Bristol-Myers Squibb | Dec 2008 | 26 |
| NCT00446433Crohn Disease · United States, France, Israel and more | 2 | Completed | Bristol-Myers Squibb | 90 | |
| NCT00424047Multiple Myeloma · Australia, Austria, Belgium and more | 3 | Completed | Bristol-Myers Squibb | Nov 1, 2005 | 351 |
| NCT00420849Multiple Myeloma · Australia, Austria, Ireland and more | 3 | Completed | Bristol-Myers Squibb | Oct 2009 | 587 |
| NCT00419250Leukemia, Lymphocytic, Chronic, B-Cell · United States, Canada, Germany and more | 1 | Completed | Bristol-Myers Squibb | Feb 1, 2010 | 52 |
| NCT00413036Lymphoma, Non-Hodgkin · United States, Canada, France and more | 2 | Completed | Bristol-Myers Squibb | Apr 2011 | 217 |
| NCT00405756Newly Diagnosed Multiple Myeloma · Australia, Austria, Belarus and more | 3 | Completed | Bristol-Myers Squibb | Nov 2009 | 459 |
| NCT00179751Pancreatic Neoplasms · United States | 2 | Terminated | Bristol-Myers Squibb | 50 | |
| NCT00179738Prostatic Neoplasms · United States | 2 | Terminated | Bristol-Myers Squibb | 40 | |
| NCT00179725Ovarian Neoplasms · United States | 2 | Terminated | Bristol-Myers Squibb | 60 | |
| NCT00179712Ovarian Neoplasms · United States | 2 | Completed | Bristol-Myers Squibb | 60 | |
| NCT00179699Carcinoma, Non-Small-Cell Lung · United States | 1 | Terminated | Bristol-Myers Squibb | 40 | |
| NCT00179686Carcinoma, Non-Small-Cell Lung · United States | 2 | Completed | Bristol-Myers Squibb | 40 |
How it is read
Names in the registry
- “Lenalidomide”, 67 entries
- “lenalidomide”, 16 entries
- “CC-5013”, 14 entries
- “Drug: Carfilzomib + Lenalidomide + Dexamethasone”, 1 entry
- “Tafasitamab plus lenalidomide”, 1 entry
Conditions, from the studies’ own filings
- Multiple Myeloma, 45 studies
- Lymphoma, Large B-Cell, Diffuse, 10 studies
- Myelodysplastic Syndromes, 8 studies
- Lymphoma, Non-Hodgkin, 5 studies
- Lymphoma, Mantle-Cell, 5 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.